Childhood brain tumours due to germline bi-allelic mismatch repair gene mutations

Clinical Genetics

Volumn 80, Issue 3, 2011, Pages 243-255

  Johannesma, Pc ^a   van der Klift, Hm ^b   van Grieken, Nct ^a   Troost, D ^c   te Riele, H ^a,d   Jacobs, Majm ^a   Postma, Tj ^a   Heideman, Dam ^a   Tops, Cmj ^b   Wijnen, Jt ^b   Menko, Fh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

DNA mismatch repair; Lynch syndrome; Papillary glioneural tumour; PMS2; Turcot syndrome

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; MISMATCH REPAIR PROTEIN PMS2; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ARTICLE; BRAIN HEMATOMA; BRAIN TUMOR; CANCER SURGERY; CASE REPORT; CHILD; CHILDHOOD CANCER; CYTOREDUCTIVE SURGERY; DNA ISOLATION; GENE MUTATION; GERMLINE MUTATION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PEDIGREE; PRIORITY JOURNAL; RECTUM ADENOMA; RECURRENT CANCER; SCHOOL CHILD;

ADENOMA; ADENOSINE TRIPHOSPHATASES; AGE OF ONSET; BRAIN NEOPLASMS; CHILD; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GERM-LINE MUTATION; GLIOMA; HETEROZYGOTE; HUMANS; MALE; MICROSATELLITE REPEATS; PEDIGREE; SIBLINGS; SYNDROME; YOUNG ADULT;

EID: 79961126297     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2011.01635.x     Document Type: Article

References (62)

1. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009: 76: 1-18.
2. Koornstra JJ, Mourits MJE, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009: 10: 400-408.
3. Chao EC, Lipkin SM. Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. Nucleic Acids Res 2006: 34: 840-852.
4. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer 2005: 4: 323-333.
5. Felton KEA, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet 2007: 71: 483-498.
6. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 2008: 124: 105-122.
7. Wang Q, Montmain G, Ruano E et al. Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum Genet 2003: 112: 117-123.
8. Menko FH, Kaspers GL, Meijer GA, Claes K, van Hagen JM, Gille JJP. A homozygous MSH6 mutation in a child with café-au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer 2004: 3: 123-127.
9. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007: 114: 97-109.
10. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010: 10: 319-331.
11. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010: 60: 166-193.
12. Stupp R, Tonn J-C, Brada M, Pentheroudakis G. on behalf of the ESMO Guidelines Working Group. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010: 21 (Suppl. 5): v190-v193.
13. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006: 7: 335-346.
14. Cahill DP, Levine KK, Betensky RA et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007: 13: 2038-2045.
15. Mojas N, Lopes M, Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev 2007: 21: 3342-3355.
16. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007: 56: 275-287.
17. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N. Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol 2007: 4: 130-134.
18. Van der Klift HM, Tops CM, Bik EC et al. Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. Hum Mutat 2010: 31: 578-87.
19. Komori T, Scheithauer BW, Anthony DC et al. Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. Am J Surg Pathol 1998: 22: 1171-1183.
20. Dim DC, Lingamfelter DC, Taboada EM, Fiorella RM. Papillary glioneuronal tumor: a case report and review of the literature. Hum Pathol 2006: 37: 914-918.
21. Newton HB, Dalton J, Ray-Chaudhury A, Gahbauer R, McGregor J. Aggressive papillary glioneuronal tumor: case report and literature review. Clin Neuropathol 2008: 27: 317-324.
22. Javahery RJ, Davidson L, Fangusaro J, Finlay JL, Gonzalez-Gomez I, McComb JG. Aggressive variant of a papillary glioneuronal tumor. Report of 2 cases. J Neurosurg Pediatr 2009: 3: 46-52.
23. Gylling AHS, Nieminen TT, Abdel-Rahman WM et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008: 29: 1351-1359.
24. Thibodeau SN, Bran G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993: 260: 816-819.
25. Oda S, Maehara Y, Ikeda Y et al. Two modes of microsatellite instability in human cancer: differential connection of defective DNA mismatch repair to dinucleotide repeat instability. Nucleic Acids Res 2005: 33: 1628-1636.
26. Giunti L, Cetica V, Ricci U et al. Type A microsatellite instability in pediatric gliomas as an indicator of Turcot syndrome. Eur J Hum Genet 2009: 17: 919-927.
27. Pollack IF, Hamilton RL, Sobol RW et al. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the Children's Oncology Group. Pediatr Blood Cancer 2010: 55: 1066-1071.
28. De Vos M, Hayward BE, Charlton R et al. PMS2 mutations in childhood cancer. J Natl Cancer Inst 2006: 98: 358-361.
29. Tan TY, Orme LM, Lynch E et al. Biallelic PMS2 mutations and a distinctive childhood cancer syndrome. J Pediatr Hematol Oncol 2008: 30: 254-257.
30. Østergaard JR, Sunde L, Okkels H. Neurofibromatosis von Recklinghausen type 1 phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6. Am J Med Genet 2005: 139A: 96-105.
31. Kratz CP, Holter S, Etzler J et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 2009: 46: 418-420.
32. Péron S, Metin A, Gardès P et al. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 2008: 205: 2465-2472.
33. Walsh MD, Buchanan DD, Cummings MC et al. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 2010: 16: 2214-2224.
34. Yip S, Miao J, Cahill DP et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009: 15: 4622-4629.
35. Martin LM, Marples B, Coffey M et al. DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data. Cancer Treat Rev 2010: 36: 518-527.
36. Barwell J, Pangon L, Hodgson S et al. Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics. J Med Genet 2007: 44: 516-520.
37. Jeans AF, Frayling I, Jasani B, Side L, Blesing C, Ansorge O. Cerebral primitive neuroectodermal tumor in an adult with a heterozygous MSH2 mutation. Nat Rev Clin Oncol 2009: 6: 295-299.
38. Damia G, D'Incalci M. Genetic instability influences drug response in cancer cells. Curr Drug Targets 2010: 11: 1317-1324.
39. Hamilton SR, Liu B, Parsons RE et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995: 332: 839-847.
40. Taylor MD, Perry J, Zlatescu MC et al. The hPMS2 exon 5 mutation and malignant glioma. J Neurosurg 1999: 90: 946-950.
41. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004: 74: 954-964.
42. Miyaki M, Nishio J, Konishi M et al. Drastic genetic instability of tumors and normal tissues in Turcot syndrome. Oncogene 1997: 15: 2877-2881.
43. De Rosa M, Fasano C, Panariello L et al. Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. Oncogene 2000: 19: 1719-1723.
44. Trimbath JD, Petersen GM, Erdman SH, Ferre M, Luce MC, Giardiello FM. Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer 2001: 1: 101-105.
45. Agostini M, Tibiletti MG, Lucci-Cordisco E et al. Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol 2005: 100: 1886-1891.
46. Auclair J, Leroux D, Desseigne F et al. Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Hum Mutat 2007: 28: 1084-1090.
47. Krüger S, Kinzel M, Walldorf C et al. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. Eur J Hum Genet 2008: 16: 62-72.
48. Gottschling S, Reinhard H, Pagenstecher C et al. Hypothesis: possible role of retinoic acid therapy in patients with biallelic mismatch repair gene defects. Eur J Pediatr 2008: 167: 225-229.
49. Etzler J, Peyrl A, Zatkova A et al. RNA-based mutation analysis identifies and unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. Hum Mutat 2008: 29: 299-305.
50. Kratz CP, Niemeyer CM, Jüttner E et al. Childhood T-cell non-Hodgkin's lymphoma, colorectal carcinoma and brain tumor in association with café-au-lait spots caused by a novel homozygous PMS2 mutation. Leukemia 2008: 22: 1078-1080.
51. Gururangan S, Frankel W, Broaddus R et al. Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro-Oncol 2008: 10: 93-97.
52. Senter L, Clendenning M, Sotamaa K et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008: 135: 419-428.
53. Roy S, Raskin L, Raymond VM, Thibodeau SN, Mody RJ, Gruber SB. Pediatric duodenal cancer and biallelic mismatch repair gene mutations. Pediatr Blood Cancer 2009: 53: 116-120.
54. Sjursen W, Bjørnevoll I, Engebretsen LF, Fjelland K, Halvorsen T, Myrvold HE. A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts. Fam Cancer 2009: 8: 179-186.
55. Vaughn CP, Robles J, Swensen JJ et al. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. Hum Mutat 2010: 31: 588-593.
56. Leenen CHM, Geurts-Giele WRR, Dubbink HJ et al. Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic PMS2 germline mutations. Clin Genet Epub 6 December 2010. DOI: 10.1111/j.1399-0004.2010.01608.x.
57. Wang Q, Lasset C, Desseigne F et al. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res 1999: 59: 294-297.
58. Bertholon J, Wang Q, Galmarini CM, Puisieux A. Mutational targets in colorectal cancer cells with microsatellite instability. Fam Cancer 2006: 5: 29-34.
59. Vilkki S, Tsao J-L, Loukola A et al. Extensive somatic microsatellite mutations in normal human tissue. Cancer Res 2001: 61: 4541-4544.
60. Poley J-W, Wagner A, Hoogmans MM et al. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer 2007: 109: 2349-2356.
61. Bougeard G, Charbonnier F, Moerman A et al. Early onset brain tumor and lymphoma in MSH2-deficient children. Am J Hum Genet 2003: 72: 213-216.
62. Hegde MR, Chong B, Blazo ME et al. A homozygous mutation in MSH6 causes Turcot syndrome. Clin Cancer Res 2005: 11: 4689-4693.